Trial Profile
A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary) ; Cisplatin; Pemetrexed
- Indications Malignant-mesothelioma
- Focus Adverse reactions; Therapeutic Use
- Acronyms MESO-02
- 04 Jan 2013 Planned number of patients changed from 140 to 24 as reported by UKCRN.
- 25 Jan 2012 Planned end date 1 Sep 2014 added as reported by UKCRN.
- 25 Jan 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by UKCRN.